Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory waldenström macroglobulinemia

Journal of Clinical Oncology

Volumn 28, Issue 8, 2010, Pages 1408-1414

  Ghobrial, Irene M ^a   Gertz, Morie ^a   LaPlant, Betsy ^a   Camoriano, John ^a   Hayman, Suzanne ^a   Lacy, Martha ^a   Chuma, Stacey ^a   Harris, Brianna ^a   Leduc, Renee ^a   Rourke, Meghan ^a   Ansell, Stephen M ^a   DeAngelo, Daniel ^a   Dispenzieri, Angela ^a   Bergsagel, Leif ^a   Reeder, Craig ^a   Anderson, Kenneth C ^a   Richardson, Paul G ^a   Treon, Steven P ^a   Witzig, Thomas E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA 2 MICROGLOBULIN; BILIRUBIN; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EVEROLIMUS; FLUDARABINE; HEMOGLOBIN; IMATINIB; IMMUNOGLOBULIN M; INTERFERON; M PROTEIN; PENTOSTATIN; RITUXIMAB; SILDENAFIL; THALIDOMIDE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PHARMACOLOGICAL BIOMARKER; RAPAMYCIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG INFILTRATE; LUNG TOXICITY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOTHERAPY; RELAPSE; REMISSION; SORE THROAT; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; BLOOD; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOXICITY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; RECURRENT DISEASE; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, PHARMACOLOGICAL; DRUG TOXICITY; FEMALE; HUMANS; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; SIROLIMUS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; WALDENSTROM MACROGLOBULINEMIA;

EID: 77950464935     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.0994     Document Type: Article

References (48)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenström's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-226, 2000
2. Ghobrial IM, Witzig TE: Waldenström's macroglobulinemia. Curr Treat Options Oncol 5:239-247, 2004
3. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al: Diagnosis and management of Waldenström's macroglobulinemia. J Clin Oncol 23:1564-1577, 2005
4. Owen RG, Treon SP, Al-Katib A, et al: Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:110-115, 2003 (Pubitemid 36506291)
5. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
6. Herrinton L, Weiss NS: Incidence of Waldenstrom's macroglobulinemia. Blood 82:3148-3150, 1993 (Pubitemid 23334943)
7. Ghobrial IM, Fonseca R, Gertz MA, et al: Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom's macroglobulinaemia. Br J Haematol 133:158-164, 2006
8. Ghobrial IM, Gertz MA, Fonseca R: Waldenstrom's macroglobulinaemia. Lancet Oncol 4:679-685, 2003
9. Kyle RA, Treon SP, Alexanian R, et al: Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:116-120, 2003 (Pubitemid 36506292)
10. Rosen N, She QB: AKT and cancer: Is it all mTOR? Cancer Cell 10:254-256, 2006
11. Yao D, Alexander CL, Quinn JA, et al: PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways. Cancer Res 66:1302-1312, 2006 (Pubitemid 43259908)
12. Li L, Ross AH: Why is PTEN an important tumor suppressor? J Cell Biochem 102:1368-1374, 2007
13. Cantrell DA: Phosphoinositide 3-kinase signalling pathways. J Cell Sci 114:1439-1445, 2001
14. Fresno Vara JA, Casado E, de Castro J, et al: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193-204, 2004
15. Hennessy BT, Smith DL, Ram PT, et al: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988-1004, 2005
16. Pene F, Claessens YE, Muller O, et al: Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21:6587-6597, 2002 (Pubitemid 35177037)
17. Dancey JE: Molecular targeting: PI3 kinase pathway. Ann Oncol 15:iv233-iv239, 2004 (suppl 4)
18. Huang J, Manning BD: A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 37:217-222, 2009
19. Toschi A, Lee E, Xu L, et al: Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: Competition with rapamycin. Mol Cell Biol 29:1411-1420, 2009
20. Das F, Ghosh-Choudhury N, Mahimainathan L, et al: Raptor-rictor axis in TGFbeta-induced protein synthesis. Cell Signal 20:409-423, 2008
21. Barquilla A, Crespo JL, Navarro M: Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation. Proc Natl Acad Sci U S A 105:14579-14584, 2008
22. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
23. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
24. Francis LK, Alsayed Y, Leleu X, et al: Combination mammalian target of rapamycin inhibitor rapamycin and hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 12:6826-6835, 2006 (Pubitemid 44876853)
25. Leleu X, Roccaro AM, Moreau AS, et al: Waldenstrom's macroglobulinemia. Cancer Lett 270:95-107, 2008
26. Ansell SM, Inwards DJ, Rowland KM Jr, et al: Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group. Cancer 113:508-514, 2008
27. Witzig TE, Geyer SM, Ghobrial I, et al: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347-5356, 2005 (Pubitemid 46206988)
28. Smith SM PB, Cisneros A, Smith S, et al: Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. J Clin Oncol 26:457s, 2008 (abstr 8514)
29. Leleu X, Jia X, Runnels J, et al: The Akt pathway regulates survival and homing in Waldenstrom's macroglobulinemia. Blood 110:4417-4426, 2007 (Pubitemid 351377808)
30. Treon SP, Gertz MA, Dimopoulos M, et al: Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 107:3442-3446, 2006
31. Dimopoulos MA, Gertz MA, Kastritis E, et al: Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 27:120-126, 2009
32. Weber D, Treon SP, Emmanouilides C, et al: Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:127-131, 2003 (Pubitemid 36506294)
33. Sargent DJ, Chan MD, Goldberg RM: A three-outcome design for phase II clinical trials. Controlled Clinical Trials 22:117-125, 2001
34. Kaplan E, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
35. Morel P, Duhamel A, Gobbi P, et al: International prognostic scoring system for Waldenstrom's macroglobulinemia. Blood 113:4163-4170, 2009
36. Kimby E, Treon SP, Anagnostopoulos A, et al: Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 6:380-383, 2006
37. Vijay A, Gertz MA: Waldenstrom's Macroglobulinemia. Blood 109:5096-5103, 2007
38. Gertz MA, Anagnostopoulos A, Anderson K, et al: Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:121-126, 2003 (Pubitemid 36506293)
39. Treon SP, Morel P, Leblond V, et al: Report of the Third International Workshop on Waldenstrom's macroglobulinemia. Clin Lymphoma 5:215-216, 2005 (Pubitemid 40614228)
40. Treon SP, Emmanouilides C, Kimby E, et al: Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 16:132-138, 2005 (Pubitemid 40124490)
41. Dimopoulos MA, O'Brien S, Kantarjian H, et al: Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med 95:49-52, 1993 (Pubitemid 23205926)
42. Kyle RA, Greipp PR, Gertz MA, et al: Waldenstrom's macroglobulinaemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737-742, 2000 (Pubitemid 30304504)
43. Dimopoulos MA, Weber D, Delasalle KB, et al: Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors. Ann Oncol 6:49-52, 1995
44. McLaughlin P, Estey E, Glassman A, et al: Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 105:4573-4575, 2005 (Pubitemid 40807273)
45. Chen CI, Kouroukis CT, White D, et al: Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1570-1575, 2007 (Pubitemid 46733084)
46. Treon SP, Hunter ZR, Matous J, et al: Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG Trial 03-248. Clin Cancer Res 13:3320-3325, 2007 (Pubitemid 46944918)
47. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of rituximab for Waldenstrom's macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45:2047-2055, 2004
48. Byrd JC, White CA, Link B, et al: Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity. Ann Oncol 10:1525-1527, 1999 (Pubitemid 30017067)